Old Web
English
Sign In
Acemap
>
authorDetail
>
Suparna B. Wedam
Suparna B. Wedam
Food and Drug Administration
Medicine
in patient
food and drug administration
Prior Therapy
MEDLINE
3
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
2021
Jeremy Mason
Yutao Gong
Laleh Amiri-Kordestani
Suparna B. Wedam
Jennifer J Gao
Tatiana M. Prowell
Harpreet Singh
Anup Amatya
Shenghui Tang
Richard Pazdur
Peter Kuhn
Gideon M. Blumenthal
Julia A. Beaver
Show All
Source
Cite
Save
Citations (0)
Overall survival in patients with breast cancer treated with a CDK 4/6 inhibitor plus fulvestrant: A U.S. Food and Drug Administration pooled analysis.
2021
Journal of Clinical Oncology
Jennifer J Gao
Joyce Cheng
Tatiana M. Prowell
Erik Bloomquist
Shenghui Tang
Suparna B. Wedam
Melanie E Royce
Danielle Krol
Christy Osgood
Gwynn Ison
Rajeshwari Sridhara
Richard Pazdur
Julia A. Beaver
Laleh Amiri-Kordestani
Show All
Source
Cite
Save
Citations (0)
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.
2021
Clinical Cancer Research
Raymond U. Osarogiagbon
Diana Merino Vega
Lola A. Fashoyin-Aje
Suparna B. Wedam
Gwynn Ison
Sol Atienza
Peter De Porre
Tithi Biswas
Jamie N. Holloway
David S. Hong
Madison M. Wempe
Richard L. Schilsky
Edward S. Kim
James L. Wade
Show All
Source
Cite
Save
Citations (2)
1
map